Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 200

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 200
---
 | Utilization of incorrect inputs to the fair value estimates for the warrant obligation related to                                 
 the Series A Convertible Preferred Stock; incorrectly recording the reclassification of the warrant obligation upon issuance as a 
 gain and not as a reclassification to stockholders’ equity;                                                                       |
| ● | Recording of accrued dividends on the Series A Convertible Preferred Stock as a liability prior to                                
 the dividends being declared;                                                                                                     |
| ● | Failure to recognize the accounting impact for the amendment to the terms of the Series A                                         
 Convertible Preferred Stock in April 2022, which the Company subsequently concluded should have been recognized as an             
 extinguishment;                                                                                                                   |
| ● | Failure to recognize deemed contribution related to the settlement of the                                                         
 Series A Convertible Preferred Stock and accrued dividends;                                                                       |

Notes Payable

| ● 
 ● | Misidentification of certain debt and equity issuance costs and incorrect association with certain of          
 the Company’s financings during the years ended December 31, 2022 and 2021;                                    
 Application of the incorrect amortization period and pattern of recognition for debt discounts recorded        
 in relation to the Company’s debt financings during the years ended December 31, 2022 and 2021;                |
|:--|:---------------------------------------------------------------------------------------------------------------|
| ● | Incorrect recognition of bifurcated derivative liabilities, as well as incorrect initial and subsequent        
 fair value measurements, in relation to the December 2021 Notes, 2022 Convertible Notes and August 2022 Notes; |
| ● | Misclassification of certain warrants issued with debt transactions during the year ended December 31,         
 2022;                                                                                                          |
| ● | Failure to recognize certain liability-classified warrants issued in exchange for services provided related    
 to the Company’s financing activities during the year ended December 31, 2022;                                 |
| ● | Incorrect application of extinguishment or conversion models in accounting for certain debt instruments        
 upon their settlement; and                                                                                     |

Initial Public Offering

| ● | Incorrect identification of deferred issuance costs incurred in relation to the initial public offering; Incorrect identification and classification of issuance costs incurred in relation to the initial public offering. |

In addition to the restatement of the consolidated
financial statements, the Company has also restated the following notes to reflect the errors described above:

| ● | Note 2 - Summary of Significant Accounting Policies (now Note 3) |
| ● | Note 5 – Notes Payable-Related Party                             |
| ● | Note 6 – Convert